Serum MG53/TRIM72 Is Associated With the Presence and Severity of Coronary Artery Disease and Acute Myocardial Infarction

Overview

Journal Front Physiol

Date 2021 Jan 4

PMID 33391037

Citations 5

Authors

Hongyang Xie

Yaqiong Wang

Tianqi Zhu

Shuo Feng

Zijun Yan

Zhengbin Zhu

Jingwei Ni

Jun Ni

Run Du

Jinzhou Zhu

Fenghua Ding

Shengjun Liu

Hui Han

Hang Zhang

Jiaxin Zhao

Ruiyan Zhang

Weiwei Quan

Xiaoxiang Yan

Affiliations

Soon will be listed here.

Abstract

Mitsugumin 53 or Tripartite motif 72 (MG53/TRIM72), a myokine/cardiokine belonging to the tripartite motif family, can protect the heart from ischemic injury and regulate lipid metabolism in rodents. However, its biological function in humans remains unclear. This study sought to investigate the relationship between circulating MG53 levels and coronary artery disease (CAD). The concentration of MG53 was measured by enzyme-linked immunosorbent assay (ELISA) in serum samples from 639 patients who underwent angiography, including 205 controls, 222 patients with stable CAD, and 212 patients with acute myocardial infarction (AMI). Logistic and linear regression analyses were used to analyze the relationship between MG53 and CAD. MG53 levels were increased in patients with stable CAD and were highest in patients with AMI. Additionally, patients with comorbidities, such as chronic kidney disease (CKD) and diabetes also had a higher concentration of MG53. We found that MG53 is a significant diagnostic marker of CAD and AMI, as analyzed by logistic regression models. Multivariate linear regression models revealed that serum MG53 was significantly corelated positively with SYNTAX scores. Global Registry of Acute Coronary Events (GRACE) scores also correlated with serum MG53 levels, indicating that MG53 levels were associated with the severity of CAD and AMI after adjusting for multiple risk factors and clinical biomarkers. MG53 is a valuable diagnostic marker whose serum levels correlate with the presence and severity of stable CAD and AMI, and may represent a novel biomarker for diagnosing CAD and indicating the severity of CAD.

Citing Articles

Circulating Myokines as Novel Biomarkers for Cardiovascular Diseases.

Lyu J, Guo D, Song Y, Zhang M, Ge F, Zhao J Rev Cardiovasc Med. 2024; 25(2):56.

PMID: 39077334 PMC: 11263177. DOI: 10.31083/j.rcm2502056.

The Potential Role of Cardiokines in Heart and Kidney Diseases.

Yang M, Luo S, Yang J, Chen W, He L, Liu D Curr Med Chem. 2023; 32(4):720-728.

PMID: 37855343 DOI: 10.2174/0109298673261760231011114150.

Tripartite Motif Protein Family in Central Nervous System Diseases.

Pan M, Li X, Xu G, Tian X, Li Y, Fang W Cell Mol Neurobiol. 2023; 43(6):2567-2589.

PMID: 36988770 PMC: 11410135. DOI: 10.1007/s10571-023-01337-5.

Protective role of MG53 against ischemia/reperfusion injury on multiple organs: A narrative review.

Xu B, Wang C, Chen H, Zhang L, Gong L, Zhong L Front Physiol. 2022; 13:1018971.

PMID: 36479346 PMC: 9720843. DOI: 10.3389/fphys.2022.1018971.

TRIM21 aggravates cardiac injury after myocardial infarction by promoting M1 macrophage polarization.

Li Z, Liu X, Zhang X, Zhang W, Gong M, Qin X Front Immunol. 2022; 13:1053171.

PMID: 36439111 PMC: 9684192. DOI: 10.3389/fimmu.2022.1053171.

References

Weisleder N, Takeshima H, Ma J . Immuno-proteomic approach to excitation--contraction coupling in skeletal and cardiac muscle: molecular insights revealed by the mitsugumins. Cell Calcium. 2007; 43(1):1-8. PMC: 3059838. DOI: 10.1016/j.ceca.2007.10.006. View

Lemckert F, Bournazos A, Eckert D, Kenzler M, Hawkes J, Butler T . Lack of MG53 in human heart precludes utility as a biomarker of myocardial injury or endogenous cardioprotective factor. Cardiovasc Res. 2016; 110(2):178-87. PMC: 4836626. DOI: 10.1093/cvr/cvw017. View

Liu F, Song R, Feng Y, Guo J, Chen Y, Zhang Y . Upregulation of MG53 induces diabetic cardiomyopathy through transcriptional activation of peroxisome proliferation-activated receptor α. Circulation. 2015; 131(9):795-804. DOI: 10.1161/CIRCULATIONAHA.114.012285. View

Doyle J, Gao J, Wang J, Yang M, Potts P . MAGE-RING protein complexes comprise a family of E3 ubiquitin ligases. Mol Cell. 2010; 39(6):963-74. PMC: 4509788. DOI: 10.1016/j.molcel.2010.08.029. View

Cao C, Zhang Y, Weisleder N, Ferrante C, Wang X, Lv F . MG53 constitutes a primary determinant of cardiac ischemic preconditioning. Circulation. 2010; 121(23):2565-74. DOI: 10.1161/CIRCULATIONAHA.110.954628. View

Wang X, Xie W, Zhang Y, Lin P, Han L, Han P . Cardioprotection of ischemia/reperfusion injury by cholesterol-dependent MG53-mediated membrane repair. Circ Res. 2010; 107(1):76-83. DOI: 10.1161/CIRCRESAHA.109.215822. View

Agewall S . Acute and stable coronary heart disease: different risk factors. Eur Heart J. 2008; 29(16):1927-9. DOI: 10.1093/eurheartj/ehn321. View

Lu X, Wang L, Chen S, He L, Yang X, Shi Y . Genome-wide association study in Han Chinese identifies four new susceptibility loci for coronary artery disease. Nat Genet. 2012; 44(8):890-4. PMC: 3927410. DOI: 10.1038/ng.2337. View

Wu H, Zhang Y, Cao C, Hu X, Fang M, Yao Y . Glucose-Sensitive Myokine/Cardiokine MG53 Regulates Systemic Insulin Response and Metabolic Homeostasis. Circulation. 2018; 139(7):901-914. DOI: 10.1161/CIRCULATIONAHA.118.037216. View

10.

Liu J, Zhu H, Zheng Y, Xu Z, Li L, Tan T . Cardioprotection of recombinant human MG53 protein in a porcine model of ischemia and reperfusion injury. J Mol Cell Cardiol. 2014; 80:10-19. PMC: 4512204. DOI: 10.1016/j.yjmcc.2014.12.010. View

11.

Chaitman B, Thygesen K, Alpert J, White H, Jaffe A, Katus H . Third universal definition of myocardial infarction. Eur Heart J. 2012; 33(20):2551-67. DOI: 10.1093/eurheartj/ehs184. View

12.

Rudnicki M, Le Grand F, McKinnell I, Kuang S . The molecular regulation of muscle stem cell function. Cold Spring Harb Symp Quant Biol. 2009; 73:323-31. DOI: 10.1101/sqb.2008.73.064. View

13.

Mathers C, Loncar D . Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006; 3(11):e442. PMC: 1664601. DOI: 10.1371/journal.pmed.0030442. View

14.

Suzuki K, Komukai K, Nakata K, Kang R, Oi Y, Muto E . The Usefulness and Limitations of Point-of-care Cardiac Troponin Measurement in the Emergency Department. Intern Med. 2018; 57(12):1673-1680. PMC: 6047987. DOI: 10.2169/internalmedicine.0098-17. View

15.

Hatakeyama S . TRIM proteins and cancer. Nat Rev Cancer. 2011; 11(11):792-804. DOI: 10.1038/nrc3139. View

16.

Newby L, Jesse R, Babb J, Christenson R, De Fer T, Diamond G . ACCF 2012 expert consensus document on practical clinical considerations in the interpretation of troponin elevations: a report of the American College of Cardiology Foundation task force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2012; 60(23):2427-63. DOI: 10.1016/j.jacc.2012.08.969. View

17.

Ozato K, Shin D, Chang T, Morse 3rd H . TRIM family proteins and their emerging roles in innate immunity. Nat Rev Immunol. 2008; 8(11):849-60. PMC: 3433745. DOI: 10.1038/nri2413. View

18.

SCANLON P, Faxon D, Audet A, Carabello B, Dehmer G, Eagle K . ACC/AHA guidelines for coronary angiography: executive summary and recommendations. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Coronary Angiography) developed in.... Circulation. 1999; 99(17):2345-57. DOI: 10.1161/01.cir.99.17.2345. View

19.

Shan D, Guo S, Wu H, Lv F, Jin L, Zhang M . Cardiac Ischemic Preconditioning Promotes MG53 Secretion Through HO-Activated Protein Kinase C-δ Signaling. Circulation. 2020; 142(11):1077-1091. DOI: 10.1161/CIRCULATIONAHA.119.044998. View

20.

Libby P . Mechanisms of acute coronary syndromes and their implications for therapy. N Engl J Med. 2013; 368(21):2004-13. DOI: 10.1056/NEJMra1216063. View